Recent Finacing
Recent Raise
TP Therapeutics is a clinical-stage, structure-based drug discovery company developing repotrectinib (TPX-0005), an oral ALK/ROS1/TRK inhibitor designed to overcome resistance, and running the TRIDENT‑1 Phase 1/2 trial.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Turning Point Therapeutics.
